Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study.

ABSTRACT:

Background

Monoclonal antibodies (mABs) targeting the calcitonin gene-related peptide (CGRP) pathway represent the first disease-specific preventive migraine therapy. Growing evidence suggests that they are effective in the preventive treatment of difficult-to-treat patients. In this study, we evaluated the psychological predictors of the outcome of treatment with the anti-CGRP monoclonal antibody erenumab in patients with chronic migraine (CM).

Methods

Seventy-five patients with CM who had already failed at least 3 preventive therapies received erenumab every 28 days for a period of 12 months. Before the first administration, patients received a full psychological evaluation using The Structured Clinical Interview for DSM-5 Clinician Version (SCID-5-CV) to assess personalit

SUBMITTER: Bottiroli S 

PROVIDER: S-EPMC8487575 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature